Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of both younger and elderly population and was defined as EBV-positive monoclonal extensive B-cell proliferative disease. The survival of patients with EBV-positive DLBCL is significantly worse than that of patients with EBV-negative DLBCL. Cells with latent EBV infection express EBER protein and may express other proteins such as EBNA and LMP proteins. EBV also induces the NFκB pathway, which may be required for the survival of the cells in DLBCL. The immunohistochemical profile is generally positive for B-cell markers CD20, CD19, CD79a, and PAX-5. CD10 and BCL6 are usually negative, while MUM1 is commonly positive. Cases with immunoblastic or plasmablastic features may lack CD20 expression. In situ hybridization for EBER is positive and is considered the most crucial test in diagnosis, with the highest diagnostic sensitivity. EBV+ DLBCL has a poor response to treatment, so rapid detection is necessary.

 

The prevalence of EBV positive DLBCL was 14.0% and 10.4% for EBER cut-off of 20% and 50%, respectively.

The EBV positive DLBCL of the elderly accounts for 8.7%–11.4% of all DLBCL in Asian countries, less than 5% in western nations. Since the introduction of rituximab, R-CHOP has become the standard treatment for CD20 positive DLBCL.

 

The competitive landscape of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          nanatinostat and valganciclovir (Nana-val)          Viracta Therapeutics     Phase 2

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033